For immune checkpoint inhibitors, a pre‐existing inflamed tumor microenvironment, characterized by high CD8+ tumor‐infiltrating lymphocytes and inflammatory gene signatures (e.g., CD8A, CD274, LAG3), correlates with improved survival with nivolumab and atezolizumab plus bevacizumab [108]. This evidence concerns the gene CD8A and neoplasm.